Great Lakes Advisors LLC Sells 14,468 Shares of Hologic, Inc. (NASDAQ:HOLX)

Great Lakes Advisors LLC lowered its stake in shares of Hologic, Inc. (NASDAQ:HOLXGet Rating) by 18.9% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 62,015 shares of the medical equipment provider’s stock after selling 14,468 shares during the period. Great Lakes Advisors LLC’s holdings in Hologic were worth $4,764,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its holdings in Hologic by 2.5% during the fourth quarter. BlackRock Inc. now owns 21,888,278 shares of the medical equipment provider’s stock worth $1,675,766,000 after buying an additional 532,526 shares during the last quarter. State Street Corp boosted its holdings in Hologic by 3.9% during the fourth quarter. State Street Corp now owns 11,332,073 shares of the medical equipment provider’s stock worth $867,584,000 after buying an additional 423,495 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Hologic by 7.4% during the fourth quarter. Geode Capital Management LLC now owns 5,790,351 shares of the medical equipment provider’s stock worth $442,486,000 after buying an additional 398,923 shares during the last quarter. TD Asset Management Inc. boosted its holdings in Hologic by 78.9% during the fourth quarter. TD Asset Management Inc. now owns 2,656,184 shares of the medical equipment provider’s stock worth $203,357,000 after buying an additional 1,171,229 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in Hologic by 18.1% during the fourth quarter. JPMorgan Chase & Co. now owns 2,642,975 shares of the medical equipment provider’s stock worth $202,346,000 after buying an additional 404,349 shares during the last quarter. Institutional investors own 92.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Bank of America cut Hologic from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $81.00 to $75.00 in a report on Wednesday, July 20th. Citigroup cut their price objective on Hologic from $78.00 to $75.00 in a report on Thursday, April 28th. BTIG Research cut Hologic from a “buy” rating to a “neutral” rating in a report on Monday, July 18th. Wells Fargo & Company cut Hologic from an “overweight” rating to an “equal weight” rating and cut their price objective for the company from $90.00 to $75.00 in a report on Monday, April 25th. Finally, UBS Group began coverage on Hologic in a report on Wednesday, July 20th. They set a “neutral” rating and a $73.00 price objective on the stock. Seven analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Hologic presently has a consensus rating of “Hold” and an average target price of $76.71.

Insiders Place Their Bets

In other Hologic news, insider Jan Verstreken sold 6,500 shares of the business’s stock in a transaction that occurred on Tuesday, May 17th. The stock was sold at an average price of $78.80, for a total transaction of $512,200.00. Following the transaction, the insider now owns 64,191 shares of the company’s stock, valued at approximately $5,058,250.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.54% of the company’s stock.

Hologic Stock Up 0.3 %

Shares of Hologic stock opened at $71.40 on Friday. The business’s 50 day simple moving average is $71.14 and its 200 day simple moving average is $72.79. Hologic, Inc. has a 52-week low of $66.58 and a 52-week high of $81.04. The firm has a market cap of $17.83 billion, a PE ratio of 12.04, a P/E/G ratio of 0.81 and a beta of 1.05. The company has a debt-to-equity ratio of 0.57, a quick ratio of 3.32 and a current ratio of 3.91.

Hologic (NASDAQ:HOLXGet Rating) last announced its earnings results on Wednesday, July 27th. The medical equipment provider reported $0.95 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.69 by $0.26. Hologic had a return on equity of 37.48% and a net margin of 28.93%. The business had revenue of $1 billion for the quarter, compared to analyst estimates of $896.71 million. During the same quarter last year, the firm earned $1.33 EPS. Hologic’s revenue for the quarter was down 14.2% compared to the same quarter last year. On average, analysts predict that Hologic, Inc. will post 5.82 earnings per share for the current fiscal year.

Hologic Company Profile

(Get Rating)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.

See Also

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLXGet Rating).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.